News

Assessing the efficacy of immunotherapy with a glutaraldehyde-modified house dust mite extract in children by monitoring changes in clinical parameters and inflammatory markers in exhaled breath

02/16/2015

Leiden, the Netherlands – In a recent open label clinical study Lozano and co-workers investigated the effect of subcutaneous specific immunotherapy on several clinical parameters and inflammatory markers in exhaled breath in paediatric patients with house dust mite induced allergic asthma.

Compared to baseline, the group treated with allergen immunotherapy showed reduced asthma severity and improved quality of life. No such changes were observed in the control group.

The inflammatory markers in exhaled breath showed little to no change in both groups compared to baseline. Further studies of these inflammatory biomarkers are needed to determine the usefulness of these markers when evaluating anti-inflammatory therapy such as specific immunotherapy.

For the publication: http://www.ncbi.nlm.nih.gov/pubmed/25471080

 

About HAL Allergy 

HAL Allergy Group is active in the field of biopharmaceuticals and is located at the Bio Science Park in Leiden, The Netherlands. Our core businesses are in the area of allergy treatment and diagnostic as well as in the area of contract manufacturing with focus on the production of biopharmaceutical products for (pre-) clinical studies. With offices in major European countries, HAL Allergy is one of the European top players, particularly in the field of allergy therapies and diagnostics. Established in 1959 HAL Allergy has long experience in developing, producing and selling allergy therapies that may reduce or erase allergic reactions. The allergy therapies are used against common allergies such as hay fever, house dust mites allergy and allergic reactions towards wasp or bee stings. The main shareholder of HAL Allergy GmbH is Droege International Group AG (http://www.droege-group.com), headquartered in Düsseldorf, Germany. More information is available on: www.hal-allergy.com. 

PDF version of this press release

 

 

About HAL Allergy

HAL Allergy Group is active in the field of biopharmaceuticals and is located at the Bio Science Park in Leiden, The Netherlands. Our core business is the development and manufacturing of therapies and diagnostics for allergic diseases. In addition, we offer contract manufacturing services focusing on the production of biopharmaceutical products for (pre-) clinical studies. With offices in major European countries, HAL Allergy is one of the European top players in the allergy immunotherapy business. Established in 1959 HAL Allergy has long experience in developing, producing and selling allergy therapies with an immuno-modulatory effect causing a reduction in symptoms and long-term disease suppression. The allergy therapies are used against common allergies such as hay fever, house dust mites allergy and allergic reactions towards wasp or bee stings. More information is available on: http://www.hal-allergy.com.   

The main shareholder of HAL Allergy GmbH is Droege International Group AG, which is an independent Advisory and Investment Company, based in Düsseldorf, Germany. More information is available on: http://www.droege-group.com. 

Contact
HAL Allergy Group

Monique Lutgens
Manager Corporate Communications
Tel. + 31 (0)88 1959010
Email: corporatecommunications@hal-allergy.com